Boundless Bio, Inc.
BOLD · Pharmaceutical Preparations · 22.5M shares · +1297%/yr ↑ dilution · EDGAR filings ↗
Grade
D46Clinical/early-stage biotech — oncology clinical, well-funded.
Strengths
- Liquidity — current ratio 8.7 (77th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Cash burnNegative free cash flow (-47.2M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Chronic dilutionShare count +1297%/yr over 1y (dilution, book value/share -95%)
- Strong balance sheetStrong balance sheet — $108M cash & investments, ~9 quarters of runway
- Notable holderHeld by 4 notable fund(s): FMR LLC, CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC +1 more (as of 2026-03-31)
Key metrics
Return on equity
-59.0%
Return on assets
-37.1%
Current ratio
8.7×
Free cash flow
-$47M
EBITDA
-$62M
Tangible book value
$99M
Cash & investments
$108M
Cash runway
9q
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07408089 ↗ | Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer Breast Cancer, Metastatic Breast Cancer | PHASE1 | Recruiting | 2029-02-28 |
| NCT05827614 ↗ | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma | PHASE1 | Terminated | 2026-03-17 |
| NCT06299761 ↗ | Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications Solid Tumor | PHASE1 | Terminated | 2025-06-25 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-23 | Material agreement2.053.025.01Exec/director changeReg FDOtherExhibits | filing ↗ |
| 2026-06-17 | Shareholder vote | filing ↗ |
| 2026-05-08 | ResultsExhibits | filing ↗ |
| 2026-04-13 | 1.02Debt obligation | filing ↗ |
| 2026-03-09 | ResultsExec/director changeExhibits | filing ↗ |
| 2025-11-05 | ResultsExhibits | filing ↗ |
| 2025-08-05 | ResultsExhibits | filing ↗ |
| 2025-06-23 | Shareholder vote | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-23 | 2026-06-22 | 0001193125-26-278570 ↗ |
| 8-K | 2026-06-17 | 2026-06-15 | 0001193125-26-273544 ↗ |
| 10-Q | 2026-05-08 | 2026-03-31 | 0001193125-26-213321 ↗ |
| 8-K | 2026-05-08 | 2026-05-08 | 0001193125-26-213269 ↗ |
| 8-K | 2026-04-13 | 2026-04-13 | 0001193125-26-153076 ↗ |
| 8-K | 2026-03-09 | 2026-03-03 | 0001193125-26-097535 ↗ |
| 10-K | 2026-03-09 | 2025-12-31 | 0001193125-26-097543 ↗ |
| 8-K | 2025-11-05 | 2025-11-05 | 0001193125-25-265707 ↗ |
| 10-Q | 2025-11-05 | 2025-09-30 | 0001193125-25-265714 ↗ |
| 10-Q | 2025-08-05 | 2025-06-30 | 0000950170-25-102391 ↗ |
| 8-K | 2025-08-05 | 2025-08-05 | 0000950170-25-102386 ↗ |
| 8-K | 2025-06-23 | 2025-06-23 | 0000950170-25-089002 ↗ |